
For first-line targeted therapy in
patients with BRAF V600 positive
metastatic melanoma
MORE THAN ONE-THIRD
OF PATIENTS RECEIVING
TAFINLAR + MEKINIST
WERE ALIVE AT 5 YEARS2
34% 5-year overall survival
rate for patients in the
TAFINLAR + MEKINIST
treatment group2
CTA
FIND OUT MORE

For the adjuvant treatment of Stage
III BRAF V600 positive melanoma
following complete resection
TAFINLAR + MEKINIST
DEMONSTRATES DURABLE
RELAPSE-FREE SURVIVAL
IN PATIENTS AT 5 YEARS1
At 5 years, over half of patients who
received TAFINLAR + MEKINIST
for 12 months in the adjuvant
setting were relapse free1